Genflow Biosciences Plc (LSE:GENF) has confirmed the successful completion of the dosing phase in its ongoing canine gene therapy trial, with no treatment-related adverse events reported. This outcome supports a favourable safety profile for the company’s SIRT6-based gene therapy and represents an important step forward in the development programme.
The study, which commenced in March 2025, is designed to evaluate the potential of the therapy to extend healthspan in canines. Initial efficacy data are expected in January 2026, with additional follow-up assessments scheduled for mid-2026. These forthcoming results will be critical in determining the broader commercial and scientific potential of the programme.
Subject to positive efficacy findings, Genflow intends to explore early-stage licensing discussions with animal health partners. Such collaborations could accelerate development while providing external validation of the platform’s potential.
More about Genflow Biosciences Plc
Founded in 2020, Genflow Biosciences Plc is a UK-based biotechnology company with research and development operations in Belgium. The group is focused on advancing gene therapies designed to slow the ageing process. Its lead programme, GF-1002, is based on a centenarian variant of the SIRT6 gene and has delivered encouraging preclinical results. In parallel, the company is also investigating therapeutic approaches for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a widespread chronic liver condition.
Leave a Reply